Reata Pharmaceuticals Inc
NASDAQ:RETA
Reata Pharmaceuticals Inc
NASDAQ:RETA
Price:
172.36 USD
Market Closed
Updated:
May 1, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of RETA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RETA
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
RETA Competitors Multiples
Reata Pharmaceuticals Inc Competitors
Reata Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Reata Pharmaceuticals Inc
NASDAQ:RETA
|
6.5B USD | 277.8 | -74.4 | -18.4 | -18.3 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
741.6B USD | 21.7 | 141.5 | 63.9 | 73.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17.3 | 48.1 | 35.2 | 38.3 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
348B USD | 4.3 | 8.6 | 11.4 | 15.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
327.1B USD | 5.4 | 896.3 | 44.6 | 87 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187B GBP | 5.1 | 39.2 | 140.6 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182B CHF | 4.2 | 13.3 | 9.7 | 16.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
175.9B CHF | 3 | 15.3 | 8.7 | 10.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
